- Home
- Publications
- Publication Search
- Publication Details
Title
EZH2: a novel target for cancer treatment
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-28
DOI
10.1186/s13045-020-00937-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma
- (2020) Da-Chuan Fan et al. AURIS NASUS LARYNX
- A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features
- (2020) Clémentine Sarkozy et al. CLINICAL CANCER RESEARCH
- The Long Non-Coding RNA Prader Willi/Angelman Region RNA5 (PAR5) Is Downregulated in Anaplastic Thyroid Carcinomas Where It Acts as a Tumor Suppressor by Reducing EZH2 Activity
- (2020) Simona Pellecchia et al. Cancers
- Targeting epigenetics in sarcomas through EZH2 inhibition
- (2020) Antoine Italiano Journal of Hematology & Oncology
- EZH2 promotes gastric cancer cells proliferation by repressing p21 expression
- (2019) Jiewei Xu et al. PATHOLOGY RESEARCH AND PRACTICE
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: Role of apolipoprotein E
- (2019) Nicole K. H. Yiew et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- AZD9291 inactivates the PRC2 complex to mediate tumor growth inhibition
- (2019) Kai-li Zhang et al. ACTA PHARMACOLOGICA SINICA
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors
- (2019) Denarda Dangaj et al. CANCER CELL
- Epigenetic Modification of Enhancer of Zeste Homolog 2 Modulates the Activation of Dendritic Cells in Allergen Immunotherapy
- (2019) Hang Li et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
- (2019) Xinyin Liu et al. Molecular Therapy-Nucleic Acids
- Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors
- (2019) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- The role and prospect of JMJD3 in stem cells and cancer
- (2019) Xiaojiao Yin et al. BIOMEDICINE & PHARMACOTHERAPY
- Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
- (2019) Alison Hirukawa et al. Cell Reports
- EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer
- (2019) Lilong Xia et al. BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
- Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
- (2019) Lauren Krill et al. GYNECOLOGIC ONCOLOGY
- CBX7 regulates stem cell-like properties of gastric cancer cells via p16 and AKT-NF-κB-miR-21 pathways
- (2018) Su-Jie Ni et al. Journal of Hematology & Oncology
- The polycomb group protein EZH2 induces epithelial–mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter
- (2018) Lu Gan et al. Journal of Hematology & Oncology
- Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function
- (2018) Lixin Wan et al. MOLECULAR CELL
- ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer
- (2018) Peijing Zhang et al. Cell Reports
- Regulation of Cellular Senescence by Polycomb Chromatin Modifiers through Distinct DNA Damage- and Histone Methylation-Dependent Pathways
- (2018) Takahiro Ito et al. Cell Reports
- Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity
- (2018) David Wang et al. Cell Reports
- Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors
- (2018) Xun Huang et al. CELL
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer
- (2018) Jing Sun et al. ONCOGENE
- Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
- (2018) Rossella Fioravanti et al. CHEMICAL RECORD
- Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells
- (2018) Youping Yang et al. OncoTargets and Therapy
- Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator
- (2018) Jung Kim et al. Cell Reports
- Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
- (2017) Yanxiao Wang et al. International Journal of Biological Sciences
- CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion
- (2017) Xin Jin et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Telomerase reverse transcriptase (TERT) - enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma
- (2017) Fahim Ahmad et al. JOURNAL OF NEUROCHEMISTRY
- EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment
- (2017) Yatao Yin et al. Journal of Neuroinflammation
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis
- (2017) Tao Tao et al. ONCOLOGY REPORTS
- The degradation of EZH2 mediated by lncRNA ANCR attenuated the invasion and metastasis of breast cancer
- (2016) Zhongwei Li et al. CELL DEATH AND DIFFERENTIATION
- Emerging roles for Polycomb proteins in cancer
- (2016) Diego Pasini et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The Functions of Histone Modification Enzymes in Cancer
- (2016) Ruilin Wang et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies
- (2016) Goro Sashida et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
- (2016) Takafumi Shimizu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Bmi-1 regulates stem cell-like properties of gastric cancer cells via modulating miRNAs
- (2016) Xiaofeng Wang et al. Journal of Hematology & Oncology
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer
- (2016) W Lu et al. ONCOGENE
- Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
- (2016) Xuejiao Song et al. Scientific Reports
- Pseudo-Reference-Based Assembly of Vertebrate Transcriptomes
- (2016) Kyoungwoo Nam et al. Genes
- Discovery, design, and synthesis of indole-based EZH2 inhibitors
- (2015) Victor S. Gehling et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
- (2015) Dongjun Peng et al. NATURE
- Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction
- (2015) Ende Zhao et al. NATURE IMMUNOLOGY
- Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity
- (2015) Jie Yin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer
- (2015) Huiming Chen et al. Oncotarget
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells
- (2014) Bryson W Katona et al. CANCER BIOLOGY & THERAPY
- Astemizole Arrests the Proliferation of Cancer Cells by Disrupting the EZH2-EED Interaction of Polycomb Repressive Complex 2
- (2014) Xiangqian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
- (2014) Sarah K. Knutson et al. PLoS One
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- Phosphorylation of EZH2 Activates STAT3 Signaling via STAT3 Methylation and Promotes Tumorigenicity of Glioblastoma Stem-like Cells
- (2013) Eunhee Kim et al. CANCER CELL
- The Polycomb Protein Ezh2 Regulates Differentiation and Plasticity of CD4+ T Helper Type 1 and Type 2 Cells
- (2013) Damon J. Tumes et al. IMMUNITY
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest
- (2012) Isabel Hidalgo et al. Cell Stem Cell
- PRC2 directly methylates GATA4 and represses its transcriptional activity
- (2012) A. He et al. GENES & DEVELOPMENT
- EZH2 couples pancreatic regeneration to neoplastic progression
- (2012) J. Mallen-St. Clair et al. GENES & DEVELOPMENT
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
- (2012) Panagiotis Ntziachristos et al. NATURE MEDICINE
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
- (2012) Sharad K. Verma et al. ACS Medicinal Chemistry Letters
- EZH2 Y641 mutations in follicular lymphoma
- (2011) C Bödör et al. LEUKEMIA
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Regulation of Tumor Angiogenesis by EZH2
- (2010) Chunhua Lu et al. CANCER CELL
- BMI1 and Mel-18 oppositely regulate carcinogenesis and progression of gastric cancer
- (2010) Xiao-Wei Zhang et al. Molecular Cancer
- Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression
- (2009) Z L Wu et al. CELL DEATH AND DIFFERENTIATION
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- EZH1 Mediates Methylation on Histone H3 Lysine 27 and Complements EZH2 in Maintaining Stem Cell Identity and Executing Pluripotency
- (2008) Xiaohua Shen et al. MOLECULAR CELL
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now